Saredutant

Summary

Saredutant (CHEMBL308148) is a phase-3 clinical-stage small molecule targeting TACR1, TACR2, and TACR3; indicated across 3 conditions including anxiety and major depressive disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 3 (TACR1, TACR2, TACR3)
• Indications: 3 conditions
• Clinical trials: 8
• Chemistry: 552.5 Da · C31H35Cl2N3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL308148
Name	Saredutant
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	104974
Molecular formula	C31H35Cl2N3O2
Molecular weight	552.5
InChIKey	PGKXDIMONUAMFR-AREMUKBSSA-N

SMILES: CC(=O)NC1(CCN(CC1)CC[C@H](CN(C)C(=O)C2=CC=CC=C2)C3=CC(=C(C=C3)Cl)Cl)C4=CC=CC=C4

IUPAC name: N-[(2S)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide

Also known as: Saredutant, Sr-48968, CHEMBL308148, SAREDUTANT, [³H]SAREDUTANT, SR-48968, SR 48968, SR 48968C

Patent coverage: 499 distinct patent families (2,269 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,232 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TACR1	NK1 receptor	Antagonist	6.6	0.7%	P25103
TACR2	NK2 receptor	Antagonist	10.25	0.2%	P21452
TACR3	NK3 receptor	Antagonist	6.2	0%	P29371

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Substance-K receptor, Substance-K receptor, Substance-P receptor, Neuromedin-K receptor, Substance-P receptor, Substance-K receptor, Substance-K receptor.

Bioactivity

ChEMBL activities: 12 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TACR2	9.89	IC50	0.13	nM	CHEMBL_ACT_394641
TACR2	9.36	IC50	0.44	nM	CHEMBL_ACT_933400
TACR2	9.3	Ki	0.5	nM	CHEMBL_ACT_121762
P05363	9.3	Ki	0.5	nM	CHEMBL_ACT_1448471
P16610	9.3	Ki	0.5	nM	CHEMBL_ACT_54248
P14600	9.29	Ki	0.51	nM	CHEMBL_ACT_1123554
TACR2	9.1	IC50	0.8	nM	CHEMBL_ACT_929275
P51144	8.92	Ki	1.2	nM	CHEMBL_ACT_54249
P30098	6.68	IC50	208	nM	CHEMBL_ACT_933401
TACR1	6.23	IC50	593	nM	CHEMBL_ACT_933399
TACR1	6.1	IC50	800	nM	CHEMBL_ACT_394640
P16610	6.03	Ki	945	nM	CHEMBL_ACT_59228

Target pathways

Aggregated over 3 target gene(s): TACR1, TACR2, TACR3.

Top Reactome pathways

4 total, by targets touching each:

Pathway	Targets	Genes
Tachykinin receptors bind tachykinins	3	TACR1, TACR2, TACR3
G alpha (q) signalling events	3	TACR1, TACR2, TACR3
Cargo recognition for clathrin-mediated endocytosis	1	TACR1
Clathrin-mediated endocytosis	1	TACR1

Dominant GO biological processes

GO term	Targets
adenylate cyclase-activating G protein-coupled receptor signaling pathway	3
phospholipase C-activating tachykinin receptor signaling pathway	3
tachykinin receptor signaling pathway	3
positive regulation of uterine smooth muscle contraction	3
positive regulation of flagellated sperm motility	3
signal transduction	3
G protein-coupled receptor signaling pathway	3
response to estradiol	2
operant conditioning	2
positive regulation of vascular permeability	2
positive regulation of blood pressure	2
response to electrical stimulus	2
regulation of uterine smooth muscle contraction	2
aggressive behavior	1
positive regulation of leukocyte migration	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230
major depressive disorder	3	MONDO:0002009	MONDO:0002009
depressive disorder	3	MONDO:0002050	MONDO:0002050

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	8

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00336713	PHASE3	COMPLETED	A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)
NCT00390533	PHASE3	COMPLETED	An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder
NCT00390650	PHASE3	COMPLETED	A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
NCT00415142	PHASE3	COMPLETED	An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder
NCT00417118	PHASE3	COMPLETED	An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
NCT00429260	PHASE3	COMPLETED	A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression
NCT00531622	PHASE3	COMPLETED	An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder
NCT00629551	PHASE3	COMPLETED	An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

108 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
SERLOPITANT	ChEMBL	Phase 3	TACR1, TACR2, TACR3
OSANETANT	ChEMBL	Phase 2	TACR1, TACR2, TACR3
TALNETANT	ChEMBL	Phase 2	TACR1, TACR2, TACR3
AMOXAPINE	ChEMBL + PubChem	Phase 4 (approved)	TACR1, TACR2
APREPITANT	ChEMBL + PubChem	Phase 4 (approved)	TACR1, TACR3
HALOPERIDOL	ChEMBL + PubChem	Phase 4 (approved)	TACR1, TACR2
PAROXETINE	ChEMBL + PubChem	Phase 4 (approved)	TACR1, TACR2
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	TACR1, TACR2
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	TACR1, TACR2
CYCLOSPORINE	ChEMBL	Phase 4 (approved)	TACR1, TACR2
ECONAZOLE	ChEMBL	Phase 4 (approved)	TACR1, TACR2
MICONAZOLE	ChEMBL	Phase 4 (approved)	TACR1, TACR2
RITONAVIR	ChEMBL	Phase 4 (approved)	TACR1, TACR2
TAMOXIFEN	ChEMBL	Phase 4 (approved)	TACR1, TACR2
TERFENADINE	ChEMBL	Phase 4 (approved)	TACR1, TACR2
AZD-7624	ChEMBL	Phase 2	TACR2, TACR3
DNK333	ChEMBL	Phase 2	TACR1, TACR2
Belzutifan	PubChem	Approved	TACR1, TACR3
Tiotropium Bromide Monohydrate	PubChem	Approved	TACR1, TACR2
ACLIDINIUM BROMIDE	ChEMBL + PubChem	Phase 4 (approved)	TACR1
FEZOLINETANT	ChEMBL + PubChem	Phase 4 (approved)	TACR3
FIDAXOMICIN	ChEMBL + PubChem	Phase 4 (approved)	TACR1
ROLAPITANT	ChEMBL + PubChem	Phase 4 (approved)	TACR1
AMIODARONE	ChEMBL	Phase 4 (approved)	TACR2
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	TACR1
BITHIONOL	ChEMBL	Phase 4 (approved)	TACR2
BOSUTINIB	ChEMBL	Phase 4 (approved)	TACR1
CARVEDILOL	ChEMBL	Phase 4 (approved)	TACR1
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	TACR2
DANAZOL	ChEMBL	Phase 4 (approved)	TACR2
DEXTROMETHORPHAN	ChEMBL	Phase 4 (approved)	TACR1
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	TACR2
DOCETAXEL	ChEMBL	Phase 4 (approved)	TACR2
DOXAZOSIN	ChEMBL	Phase 4 (approved)	TACR1
EBASTINE	ChEMBL	Phase 4 (approved)	TACR2
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	TACR2
GENTIAN VIOLET	ChEMBL	Phase 4 (approved)	TACR2
GRAMICIDIN	ChEMBL	Phase 4 (approved)	TACR2
HALOPROGIN	ChEMBL	Phase 4 (approved)	TACR2
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	TACR2
ITRACONAZOLE	ChEMBL	Phase 4 (approved)	TACR1
KETOCONAZOLE	ChEMBL	Phase 4 (approved)	TACR2
LANSOPRAZOLE	ChEMBL	Phase 4 (approved)	TACR1
LOVASTATIN	ChEMBL	Phase 4 (approved)	TACR2
MONTELUKAST	ChEMBL	Phase 4 (approved)	TACR2
NEFAZODONE	ChEMBL	Phase 4 (approved)	TACR1
NELFINAVIR	ChEMBL	Phase 4 (approved)	TACR2
NETUPITANT	ChEMBL	Phase 4 (approved)	TACR1
NILOTINIB	ChEMBL	Phase 4 (approved)	TACR1
OXICONAZOLE	ChEMBL	Phase 4 (approved)	TACR2
PACLITAXEL	ChEMBL	Phase 4 (approved)	TACR2
PASIREOTIDE	ChEMBL	Phase 4 (approved)	TACR2
RALOXIFENE	ChEMBL	Phase 4 (approved)	TACR2
SAQUINAVIR	ChEMBL	Phase 4 (approved)	TACR2
SULCONAZOLE	ChEMBL	Phase 4 (approved)	TACR2
SULOCTIDIL	ChEMBL	Phase 4 (approved)	TACR2
THIOTHIXENE	ChEMBL	Phase 4 (approved)	TACR1
TRAZODONE	ChEMBL	Phase 4 (approved)	TACR1
VINORELBINE	ChEMBL	Phase 4 (approved)	TACR2
CASOPITANT	ChEMBL	Phase 3	TACR1